FDA FINAL CME POLICY ALLOWS GENERAL STATEMENT ON OFF-LABEL USES INSTEAD OF DISCLOSURE FOR EACH USE DISCUSSED; WRITTEN AGREEMENTS LESS EMPHASIZED
Executive Summary
FDA will consider a general statement on unapproved drug uses during continuing medical education programs as sufficient disclosure under the agency's final "Guidance for Industry: Industry-Supported Scientific and Educational Activities" released Dec. 3.
You may also be interested in...
Website “Influence” Shouldn’t Make Firms Responsible For Content – PhRMA
FDA’s social media guidance on interactive promotional materials should require companies to submit only content that they have control over, PhRMA and BIO tell FDA; industry asks for clarification on a firm’s responsibility for user-generated content, such as comments on off-label use.
Sharing The Risk: Companies Turn To Multi-Sponsored Educational Programs
Pharma companies are turning to multi-sponsored continuing medical education programs as a way to mitigate risks in a climate where company-sponsored educational programs draw increased scrutiny
Sharing The Risk: Companies Turn To Multi-Sponsored Educational Programs
Pharma companies are turning to multi-sponsored continuing medical education programs as a way to mitigate risks in a climate where company-sponsored educational programs draw increased scrutiny